An Intervention Study for Adults with Moderate Plaque Psoriasis

This study is currently closed to enrollment.

Efficacy Assessor-blinded Study of Risankizumab Compared to Apremilast for the Treatment of Adult Subjects with Moderate Plaque Psoriasis who are Candidates for Systemic Therapy

woman scratching her hand

 

AGE: 18 years and older
SEX AT BIRTH: All
TYPE: Interventional Drug Study
CONDITION: Plaque psoriasis
HEALTHY PARTICIPANTS: No
LOCATION: UH Cleveland Medical Center

Study Purpose

The purpose of this study is to evaluate if the study drug, Risankizumab, is more effective to Apremilast in the treatment of moderate plaque psoriasis. The effectiveness of Risankizumab will be evaluated in subjects who have not been treated with Risankizumab and in subjects who switch from Apremilast to Risankizumab.